| 1 |
33960104 | Novel CTRP8-RXFP1-JAK3-STAT3 axis promotes Cdc42-dependent actin remodeling for enhanced filopodia formation and motility in human glioblastoma cells. | 2022 Jan |
3 |
| 2 |
35139477 | Synthesis and evaluation of tofacitinib analogs designed to mitigate metabolic activation. | 2022 Apr |
4 |
| 3 |
35411095 | JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. | 2022 Jun |
2 |
| 4 |
35505771 | Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease. | 2022 Jan |
1 |
| 5 |
32647892 | Interleukin-7 and interleukin-15 drive CD4+CD28null T lymphocyte expansion and function in patients with acute coronary syndrome. | 2021 Jul 7 |
1 |
| 6 |
32738245 | Granzyme B Inhibition by Tofacitinib Blocks the Pathology Induced by CD8 T Cells in Cutaneous Leishmaniasis. | 2021 Mar |
1 |
| 7 |
32829958 | Pharmacology and safety of tofacitinib in ulcerative colitis. | 2021 Jan |
1 |
| 8 |
32873116 | Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis. | 2021 Dec |
1 |
| 9 |
33466582 | JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL). | 2021 Jan 14 |
1 |
| 10 |
33517393 | Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy. | 2021 Apr 26 |
1 |
| 11 |
33613945 | Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis - NICE guidance. | 2021 |
1 |
| 12 |
34547646 | Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma. | 2021 Nov |
2 |
| 13 |
34660145 | Tofacitinib Treatment in Patients With Active COVID-19 Infection. | 2021 Sep |
1 |
| 14 |
31833760 | "Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4": Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping. | 2020 Feb 17 |
1 |
| 15 |
31956784 | Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases. | 2020 Jan 14 |
1 |
| 16 |
31970549 | Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement. | 2020 Mar |
2 |
| 17 |
32843425 | Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations. | 2020 Aug |
1 |
| 18 |
30806707 | Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. | 2019 Feb 1 |
1 |
| 19 |
30930775 | Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. | 2019 |
1 |
| 20 |
30997845 | Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. | 2019 Jul |
1 |
| 21 |
31096817 | Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. | 2019 Jun |
1 |
| 22 |
31288716 | Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors. | 2019 |
2 |
| 23 |
31545408 | Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene. | 2019 Nov |
1 |
| 24 |
31546174 | Docking structurally similar analogues: Dealing with the false-positive. | 2019 Dec |
1 |
| 25 |
29254929 | Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis. | 2018 May 1 |
1 |
| 26 |
29434279 | Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. | 2018 May |
2 |
| 27 |
29452839 | Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor. | 2018 May 1 |
1 |
| 28 |
29458040 | Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia. | 2018 Apr 15 |
1 |
| 29 |
29471605 | [Emerging Therapies: What Are Promising in the Near Future?] | 2018 Feb 25 |
1 |
| 30 |
29942363 | The role of the JAK/STAT signal pathway in rheumatoid arthritis. | 2018 Jun |
2 |
| 31 |
30034188 | Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients. | 2018 May-Jun |
1 |
| 32 |
30207045 | Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus. | 2018 Sep |
1 |
| 33 |
27998802 | Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges? | 2017 Feb |
1 |
| 34 |
28107751 | Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques. | 2017 Mar |
2 |
| 35 |
28371574 | Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever. | 2017 Jan-Mar |
1 |
| 36 |
28382662 | Successful targeted treatment of mast cell activation syndrome with tofacitinib. | 2017 Aug |
1 |
| 37 |
28632888 | Excellent response to tofacitinib treatment in a patient with alopecia universalis. | 2017 Jun |
1 |
| 38 |
28790099 | GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis. | 2017 Aug 7 |
1 |
| 39 |
28829236 | A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. | 2017 Oct |
1 |
| 40 |
29139090 | Tofacitinib: A Review in Rheumatoid Arthritis. | 2017 Dec |
2 |
| 41 |
29296924 | T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib). | 2017 Dec 26 |
3 |
| 42 |
25787234 | Tofacitinib, a novel JAK3 inhibitor, as a potential cause of distal symmetric polyneuropathy. | 2016 Jun |
1 |
| 43 |
26738536 | Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. | 2016 Mar 10 |
3 |
| 44 |
27003097 | An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed. | 2016 Apr |
1 |
| 45 |
27163538 | Targeting JAK/STAT Signaling to Prevent Rejection After Kidney Transplantation: A Reappraisal. | 2016 Sep |
1 |
| 46 |
27329723 | STAT5 induces miR-21 expression in cutaneous T cell lymphoma. | 2016 Jul 19 |
2 |
| 47 |
27555492 | Insights into kinetic mechanism of Janus kinase 3 and its inhibition by tofacitinib. | 2016 Dec 15 |
3 |
| 48 |
27932144 | Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro. | 2016 Nov |
1 |
| 49 |
29932316 | [Research progress of JAK-3 kinase and its inhibitors]. | 2016 Oct |
1 |
| 50 |
25146434 | Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia. | 2015 May |
3 |